Skip to main content
. 2012 Sep 17;7:158. doi: 10.1186/1748-717X-7-158

Table 3.

Three and 5-year FFF rates from the start of any treatment with comparison of patient-, tumor- and treatment-related characteristics (univariate analysis)

Characteristics Events (n)/patients (n) 3-year FFF rates - % [range] 5-year FFF rates - % [range] Log-rank test
p-value
Treatment
0.0311*
 IG-IMRT
3/49
95.87% [84.49%-98.95%]
93.14% [79.96%-97.76%]
 RP + IMRT
9/49
87.61% [74.48%-94.24%]
76.46% [58.31%-87.50%]
Age
 ≤ 66.8 years
5/49
91.74% [79.47%-96.82%]
88.35% [73.58%-95.12%]
0.595
 > 66.8 years
7/49
91.59% [79.08%-96.76%]
83.00% [67.17%-91.65%]
Tumor stage
 T1
8/60
91.44% [80.61%-96.35%]
84.37% [70.75%-91.99%]
0.758
 T2
4/38
92.11% [77.49%-97.38%]
87.72% [69.57%-95.38%]
Gleason score
 ≤ 6
5/58
96.52% [86.80%-99.12%]
89.15% [75.57%-95.40%]
0.135
 7
7/40
84.68% [68.98%-92.82%]
81.29% [64.45%-90.69%]
Pretherapeutic PSA
 ≤ 8.7 ng/mL
4/49
93.83% [82.08%-97.97%]
90.99% [77.46%-96.57%]
0.250
 > 8.7 ng/mL
8/49
89.55% [76.67%-95.52%]
80.69% [64.58%-90.01%]
Concomitant ADT
 No
12/78
89.53% [80.13%-94.63%]
82.02% [70.12%-89.52%]
0.070
 Yes
0/20
100 [ND – ND]
100 [ND – ND]
Adjuvant ADT
 No
12/84
90.29% [81.51%-95.03%]
83.44% [72.36%-90.36%]
0.156
 Yes 0/14 100 [ND – ND] 100 [ND – ND]  

FFF: Freedom from biochemical failure; ADT: androgen deprivation therapy; * the definition of biochemical failure in the RP + IMRT group is a PSA threshold of ≥ 0.1 ng/mL.